Sign inCreate account

Report workspace tools

NCT03894007TERMINATEDanonymous

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

Sponsor

Source record

Renske Altena

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Epirubicin, Cyclophosphamide, Atezolizumab, Trastuzumab emtansine, Paclitaxel

Indication / condition

AI-normalized

Early-stage Breast Cancer

Intervention

Source record

Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Epirubicin, Cyclophosphamide, Atezolizumab, Trastuzumab emtansine, Paclitaxel

Source & freshness

Source record

NCT ID

NCT03894007

Original source

ClinicalTrials.gov

Source last updated

Sep 23, 2021

Ingested at

Jun 08, 2026

Internal sync

Jun 08, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03894007

Title

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

Sponsor

Renske Altena

Status

TERMINATED

Phase

PHASE2

Condition raw

Early-stage Breast Cancer, HER2-positive Breast Cancer

Condition normalized

Early-stage Breast Cancer, HER2-positive Breast Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Epirubicin, Cyclophosphamide, Atezolizumab, Trastuzumab emtansine, Paclitaxel

Target normalized

Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Epirubicin, Cyclophosphamide, Atezolizumab, Trastuzumab emtansine, Paclitaxel

Interventions

Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Epirubicin, Cyclophosphamide, Atezolizumab, Trastuzumab emtansine, Paclitaxel

Public preview

Source record

This is a phase 2 study evaluating medical treatment before surgery in HER2-amplified early breast cancer patients. Patients receive chemotherapy with HER2-targeted antibodies and are randomised to receive the checkpoint inhibitor atezolizumab or not.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03894007

Status

TERMINATED

Phase

PHASE2

Sponsor

Renske Altena

Executive brief

Investment-Ready Snapshot

This is a phase 2 study evaluating medical treatment before surgery in HER2-amplified early breast cancer patients. Patients receive chemotherapy with HER2-targeted antibodies and are randomised to receive the checkpoint inhibitor atezolizumab or not.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 23, 2021
Internal syncJun 08, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03894007

Indication

Early-stage Breast Cancer

Modality

small molecule

Target

Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Epirubicin, Cyclophosphamide, Atezolizumab, Trastuzumab emtansine, Paclitaxel

Intervention

Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Epirubicin, Cyclophosphamide, Atezolizumab, Trastuzumab emtansine, Paclitaxel

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.